Testing TQB2101 for advanced solid tumors
Part of Cancer, Digestive system, Lungs & breathing, Skin clinical trials.
This trial tests an experimental drug called TQB2101 for people with advanced solid tumors that have not responded to standard treatments. The study aims to understand how the body handles the drug and what side effects may occur. It may be an option if your tumor has a specific marker called ROR1.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Have an advanced solid tumor that standard treatments did not help
- Be in generally good health with normal liver, kidney, and blood function
- Have at least one tumor that can be measured on scans (except in the first part of the study)
- Agree to use effective birth control during the study and for 6 months after
- Not have other active cancers, serious heart problems, or uncontrolled infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called TQB3126 for people with breast cancer that has worsened after previous treatments. The goal is to see if the drug is safe, how your body processes it, and if it can help shrink or slow the cancer.
This study tests a new drug, TQB2102, for people with HER2-negative breast cancer that has spread and no longer responds to standard treatments. The goal is to see if the drug can shrink tumors or slow the cancer.
This trial tests a new drug called TQB3142 in people with advanced cancers that have not responded to standard treatments. The goal is to find a safe dose and see how the drug works in the body.
This trial is testing a new oral medication called TQB3107 for people with advanced solid tumors (cancer that has spread or cannot be removed). The study aims to see if the drug is safe and how well it works.
This phase 1 trial tests an experimental drug called TQB2252 for people with advanced cancers that have not responded to standard treatments. The drug blocks a protein called LAG3 to help the immune system attack cancer cells.
This trial tests a new injection called TQB2922 for people with advanced non-squamous non-small cell lung cancer who have already tried standard treatments. The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.